Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13021639 | 0.85 | POLB (0.41) | POLBHTR1DCYP3A4LMNATP53 | |
| SCHEMBL19504378 | 0.83 | CNR2 (0.33) | TUBB1LMNAHTR2AKIF11 | |
| SCHEMBL13208392 | 0.82 | TUBB1 (0.38) | TUBB1POLBHTR1DCYP3A4LMNA | |
| SCHEMBL15828699 | 0.81 | POLB (0.43) | TUBB1POLBHTR1DCYP3A4LMNA | |
| SCHEMBL12390583 | 0.80 | POLB (0.44) | POLBHTR1DLMNAHPGDALOX15 | |
| SCHEMBL19504309 | 0.80 | FGFR2 (0.33) | POLBHTR1DCYP3A4LMNATP53 | |
| SCHEMBL12016747 | 0.76 | POLB (0.46) | POLBHTR1DCYP3A4LMNATP53 | |
| SCHEMBL13558892 | 0.76 | HIF1A (0.39) | POLBCYP3A4LMNATP53HPGD | |
| SCHEMBL12724998 | 0.76 | LMNA (0.31) | CYP3A4LMNATP53HPGDALOX15 | |
| SCHEMBL19803230 | 0.76 | HTR1D (0.35) | HTR1DCYP3A4LMNATP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021316-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021316-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, TP53 | TUBB1 314/4885POLB 563/4885HTR1D 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.